32 results about "Poxvirus Infections" patented technology

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.

The present invention relates to 2'-fluoro-6'-methylene carbocyclic nucleosides and nucleotides, pharmaceutical compositions containing these nucleosides and nucleotides, and their use in the treatment or prophylaxis of poxvirus infections and secondary disease states and conditions thereof.

Provided herein are methods of producing immunoglobulin Y (IgY) antibodies against monkeypox virus. The method includes immunizing hens with a peptide encoding at least one immunogenic domain of A29 fusion protein from the monkeypox virus and isolating the IgY antibodies against the A29 fusion protein from yolks of eggs laid by the immunized hens. Pharmaceutical compositions containing the IgY antibodies and methods of inhibiting or treating monkeypox virus infection are also provided.

The invention discloses an application of diphyllin in preparation of drugs for inhibiting poxvirus and preventing or treating poxvirus infection, the poxvirus is common orthopoxvirus poxvirus, the poxvirus comprises vaccinia virus (VACV), vaccinia virus (CPXV) and rabbit poxvirus mucinoma virus (MYXV), the content of diphyllin is in a range of 1.25-2.5 [mu] M / mL, and the content of diphyllin is in a range of 1.25-2.5 [mu] M / mL. The compound has a remarkable inhibiting effect on infection of poxvirus family members such as CPXV, is expected to be used as a medicine for preventing and treating infection of CPXV and other poxviruses, and has important significance on prevention and control of diseases related to poxvirus infection.

The invention belongs to the technical field of biology, and discloses an anti-monkey pox virus E8 antibody or an antigen binding fragment thereof and application thereof. The invention provides an anti-monkey pox virus E8 monoclonal antibody 2F6, 9G4, 9H1 or 10E11, which can specifically recognize and target orthopox viruses such as monkey pox, vaccinia and the like, and shows efficient virus neutralizing capacity. The clinical application value of preventing and treating orthopoxvirus infection is realized; the compound can be used for detecting orthopoxvirus, diagnosing diseases related to orthopoxvirus infection and preventing and / or treating orthopoxvirus infection and / or diseases related to orthopoxvirus infection.

The invention discloses a novel method for rapidly detecting monkey pox virus infection, an isothermal amplification-CRISPR / Cas12b single-tube step-by-step detection method established by the research has high sensitivity and specificity on monkey pox virus detection, expensive equipment is not needed, and detection can be completed within 50 min. Clinical sample detection results show that the method has good detection consistency with qPCR, the method has the potential of rapidly and accurately screening monkey pox virus infection in clinical practice, and meanwhile, a thought is provided for establishing a rapid and sensitive detection method for other infectious disease pathogens.

The present disclosure relates generally to vaccines against orthopoxviruses, and methods for making and using such vaccines. In particular, in some embodiments, the present disclosure relates to nanoparticle-derived vaccines, and compositions based thereon, that elicit an immune response against an orthopoxvirus. The present disclosure further relates to the use of vaccines and vaccine compositions for preventing; decreasing the severity, morbidity and / or mortality of; shortening the duration of; and / or reducing the symptoms of, a poxvirus infection, such as, for example, an orthopoxvirus infection.

The invention provides an anti-orthopoxvirus monoclonal antibody and application thereof, the monoclonal antibody is obtained by screening through a flow cytometry sorting technology and a single cell PCR technology, has a unique CDR partition, and is mainly used for recognizing L1R (M1R) antigen protein of orthopoxvirus. The affinity of the antibody to VARV (Vector Activated Receptor Virus), VACV (Vector Activated Receptor Virus), CPXV (Cytopoxvirus) and MPXV (Metapoxvirus) of orthopoxvirus is 1.84 nM, 1.46 nM, 2.71 nM and 2.57 nM respectively. In a virus neutralization experiment, the IC50 of the antibody and mature virions in vaccinia virus cells is 37.93 pM. In a monkey pox virus infected mouse model, the antibody can treat a monkey pox virus infected mouse. The monoclonal antibody disclosed by the invention has the characteristics of high expression, high neutralizing activity and good broad spectrum, can be used for industrial production, and can be applied to coping with orthopoxvirus infection outbreak possibly occurring in the future.

The invention belongs to the field of biological medicine, and particularly relates to application of Thaflavanin-3 '-Gallate or NAD < + > in preparation of a product for preventing or treating monkey pox virus infection. The invention finds that the protein OPG188 of the monkey pox virus can significantly inhibit the natural immune process of the monkey pox virus, compounds Thaflavanin-3 '-Gallate and NAD + which have the highest affinity with the OPG188 are screened out through molecular virtual docking, and the action effects of the compounds are verified through cell experiments and molecular experiments, which indicates that the Thaflavanin-3'-Gallate and NAD + have the effect of inhibiting the replication of the monkey pox virus. The compound can be used for preparing medicines for resisting monkey pox virus infection.

The invention belongs to the technical field of biological medicines, discloses an application of erythromycin ethyl succinate in preparation of a medicine for preventing and / or treating poxvirus infection, and also provides a medicine and a medicine composition containing erythromycin ethyl succinate. The traditional Chinese medicine composition can effectively inhibit interaction between viruses and host cells and improve virus infection symptoms, and has the advantages of filling the blank in the prior art and providing a novel, safe and effective anti-poxvirus treatment scheme.

This invention discloses a monkeypox virus nanoparticle vaccine based on an HBc-VLP vector, its preparation method, and its application, belonging to the field of biomedical technology. The vaccine uses HBc-VLP as a backbone with SpyCatcher sites on its surface. Through a SpyTag / SpyCatcher coupling system, antigenic polypeptides derived from the monkeypox virus M1R protein (containing overlapping epitopes for B cells and T cells) are loaded onto the VLP surface in a high-density, directed, and stable manner. This design mimics the structure of natural viral particles and can efficiently activate humoral and cellular immunity. The epitopes, screened by immunoinformatics, exhibit high antigenicity, broad-spectrum HLA affinity, and are non-toxic and non-sensitizing. This invention also provides an immunomodulatory composition containing this vaccine and its application in the preparation of drugs for the prevention or treatment of monkeypox virus infection. The vaccine preparation process is simple, has strong antigen compatibility, and has good industrialization prospects.

The invention provides application of a milk-derived active component in preparation of an orthopoxvirus inhibitor. The milk-derived active component comprises one or more of lactoferrin, whey protein, milk fat globule membrane and osteopontin. The milk-derived active component has the activity of remarkably inhibiting orthopox virus infection, and is a potential preparation for treating monkey pox and vaccinia virus infectious diseases. The lactoferrin can inhibit virus infection in the whole life cycle of the virus, has important medicinal value, and is a promising candidate preparation for treating infectious diseases of monkey pox virus and other orthopox virus.

This invention provides the application of ciclopiroxamide in the preparation of anti-poxvirus drugs, belonging to the field of biomedical technology. The application of ciclopiroxamide in the preparation of anti-poxvirus drugs. This invention demonstrates for the first time that ciclopiroxamide possesses highly efficient anti-poxvirus activity, inhibiting the infection of host cells by orthopoxvirus and goatpoxvirus genera, while simultaneously inhibiting poxvirus replication. Therefore, ciclopiroxamide can be used in the treatment and drug development of poxvirus-related diseases. This invention opens up new avenues for the use of ciclopiroxamide, providing a new means for the treatment of poxvirus-related diseases in the livestock industry and biomedical fields.

A substance for the treatment of poxvirus including Anacardium occidentale seed extract oil, sunflower oil and an excipient. The Anacardium occidentale seed extract oil and the sunflower oil are mixed and heated together at a predetermined temperature. The excipient is aloe vera or white petrolatum. The substance is topically applied in human skin for relief of poxvirus infection symptoms.

An immunoassay is described that enables a precise evaluation of immune responses in individuals exposed to Mpox or vaccinated with MVA, with high sensitivity and specificity. The serological assay targets three Orthopoxvirus antigens, MPXV-B6R, MPXV-A27L, and VACV-B5R, which are sufficient to quantify antibody responses to both MVA-vaccination (VACV-B5R) and, separately, infection (MPXV-B6R). The three antigen titres can be combined in a simple function [sum of ((MPXV-B6R) / VACV-B5R) and (MPXV-A27L)] to provide a numerical test score that can be compared with a reference (threshold) value to differentiate between post infection and post vaccination immune responses.

The invention discloses an application of a compound in preparation of a product for resisting poxvirus infection. The compound is PKM2-IN-1. It is clear that PKM2-IN-1 has a remarkable broad-spectrum anti-poxvirus effect for the first time, safety is good, replication of the poxvirus is effectively inhibited, and a new clinical treatment means is provided for preventing and treating diseases caused by the poxvirus.

The invention discloses a humanized antibody aiming at vaccinia virus membrane protein A33R and application of the humanized antibody. The amino acid sequence of a heavy chain variable region of the humanized antibody is as shown in SEQ ID No.1, and the amino acid sequence of a light chain variable region of the humanized antibody is as shown in SEQ ID No.2. Experiments prove that in an in-vivo protection experiment, mice can be completely protected from death caused by vaccinia virus infection by injecting the humanized antibody in advance, and the humanized antibody has great potential in treatment and prevention of vaccinia virus infection.

Provided herein are antibodies and functional fragments thereof for treating or preventing viral diseases, for example pox viral diseases, for example smallpox and monkey pox. Any antibody or functional fragment thereof described herein can be an engineered antibody or engineered antibody fragment. Also, provided herein are compositions and pharmaceutical compositions containing one or more antibodies or functional fragments thereof. Further provided herein are kits containing one or more antibodies or functional fragments thereof, and methods, dosing schedules, dosage amounts, and routes of administration of antibodie(s) and functional fragment(s) thereof. Finally are provided methods of making antibodies and functional fragments thereof.

The current disclosure includes a modular vaccine platform. Also included are monkeypox vaccines that protect against pathogenic monkeypox (Mpox) species, as well as their variants. The vaccines typically include a modified mRNA encoding at least one immunogen, such as a viral envelope protein, cell surface binding protein, or a biologically effective / significant fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions that can be used to generate an immune response to pathogens, including monkeypox virus, in a subject.

The application relates to application of clofarabine in preparation of a medicine for preventing or treating poxvirus infection. 50 The IC50 of inhibiting vaccinia virus is 0.44 muM, and the IC50 of inhibiting monkeypox virus is 0.06 muM. 50 Since the drug target points of deoxyribonucleotide large subunits of monkeypox virus, vaccinia virus, smallpox virus and other poxviruses are extremely conservative, clofarabine has the potential of broad-spectrum anti-poxvirus, and the toxic effect of clofarabine on Vero cells is extremely low. The application has important significance for prevention and treatment of poxviruses.

The invention relates to application of apigenin in preparation of a medicine for preventing and / or treating monkey pox virus infection, and belongs to the technical field of biological medicine. A natural product apigenin is selected, the anti-monkey pox virus activity of the apigenin is researched, and the result shows that the apigenin can effectively inhibit expression and replication of monkey pox viruses in host cells in vitro and shows remarkable antiviral activity. In addition, the apigenin is wide in source and low in cost, a new choice is provided for preparation of the anti-monkey pox virus medicine, and the apigenin has good popularization and application prospects.

The application relates to the technical field of biological medicine, and particularly discloses an anti-positive poxvirus monoclonal antibody and application thereof. The anti-positive poxvirus monoclonal antibody provided by the application is 4H4, 12C3 or 11C9. The anti-positive poxvirus monoclonal antibody provided by the application can specifically recognize and target monkeypox, vaccinia and other positive poxviruses, and shows high virus neutralization capacity, and can be used for preparing a medicine for preventing and / or treating positive poxvirus infection and / or a disease related to positive poxvirus infection, or preparing a detection product for detecting positive poxviruses and diagnosing a disease related to positive poxvirus infection.

This invention relates to antibodies for detecting monkeypox virus and their applications, belonging to the field of biotechnology. This invention screened three antibodies, including antibody 18F7, antibody 27C3, and antibody 27F1; all antibodies contain a heavy chain variable region and a light chain variable region. The heavy chain variable region of antibody 18F7 contains amino acid sequences as shown in SEQ ID NO. 1-3, and the light chain variable region contains amino acid sequences as shown in SEQ ID NO. 4-6; the heavy chain variable region of antibody 27C3 contains amino acid sequences as shown in SEQ ID NO. 7-8 and VH-CDR3:WDY, and the light chain variable region contains amino acid sequences as shown in SEQ ID NO. 9-11; the heavy chain variable region of antibody 27F1 contains amino acid sequences as shown in SEQ ID NO. 12-14, and the light chain variable region contains amino acid sequences as shown in SEQ ID NO. 15-17. Antibody 18F7 can bind not only to the A29L protein but also to its homologs A28L, 192, and A30L. Antibodies 27C3 and 27F1 specifically recognize the A29L protein. All three antibodies exhibit high binding affinity to the A29L protein, making them suitable for sensitive and specific detection of monkeypox virus A29L protein and applicable for the clinical diagnosis of monkeypox virus infection-related diseases.

The invention discloses application of TMEM33 as a target spot in preparation of a product for resisting poxvirus infection. By constructing a knockout cell model and an overexpression cell model, it is clear that TMEM33 is a key target spot for resisting poxvirus infection, and the expression of TMEM33 is improved, so that poxvirus replication is remarkably inhibited. The invention provides technical support for developing novel anti-poxvirus infection related products, and has wide application prospects.

The application belongs to the technical field of medicine. The monkeypox virus surface membrane antigen H3L protein expressed by Escherichia coli is used as an antigen, and Balb / c mice are inoculated with the H3L protein emulsified with Freund's complete adjuvant, and the antigen is co-immunized for three times. The mouse spleen cells are fused with myeloma cells SP2 / 0 cells to prepare H3L specific hybridoma cells, and then the hybridoma is cloned and detected to screen the hybridoma cells specific to the H3L antibody. After three rounds of antigen specific screening, a high-affinity poxvirus murine monoclonal antibody is obtained, the amino acid sequence of the heavy chain variable region domain is shown as SEQ ID NO. 1 in the sequence table, and the amino acid sequence of the light chain variable region domain is shown as SEQ ID NO. 3 in the sequence table. The antibody has good binding capacity with the antigen H3L through ELISA detection, and has good protection in the in vitro neutralization experiment. The antibody can not only be applied to the research and treatment of diseases caused by poxvirus infection, but also can be used as a tool for poxvirus detection and treatment, and has potential application value in detecting poxvirus infection.

The invention discloses an anti-orthopoxvirus antibody or an antigen binding fragment thereof and application of the anti-orthopoxvirus antibody or the antigen binding fragment. The antibody or the antigen binding fragment thereof can specifically recognize and target orthopoxvirus, and shows efficient virus neutralizing capability; the clinical application value of preventing and treating orthopoxvirus infection is realized; the compound can be used for detecting orthopoxvirus, diagnosing diseases related to orthopoxvirus infection and preventing and / or treating orthopoxvirus infection and / or diseases related to orthopoxvirus infection.

The application discloses a humanized antibody for poxvirus membrane-associated protein L1R and application thereof. An amino acid sequence of a heavy chain variable region of the humanized antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. Experiments prove that the humanized antibody provided by the application can efficiently neutralize vaccinia virus and monkeypox virus in an in-vitro experiment, and in an in-vivo protection experiment, the antibody injected in advance can completely protect mice from death caused by vaccinia virus infection. In addition, the humanized antibody provided by the application is the best monoclonal antibody among currently reported poxvirus non-complement-dependent neutralizing antibodies, and has great potential in treatment and prevention of poxvirus infection.

Provided herein are methods for preventing an mpox virus infection, reducing the effects of an mpox virus infection, or inducing a protective immune response against an mpox virus in a subject, such as a human, comprising administering to the subject a pharmaceutical composition comprising a modified vaccinia Ankara viral vector encoding programmed cell death protein 1 (PD-1) inhibitory peptide LD10 (MVA-LD10).